[CLSTR]
< Back to all clusters
[HEALTH] · United States · 5 sources

started · updated

Part of situation: Eli Lilly retatrutide development and black market issues (11 clusters)

Eli Lilly reports strong phase‑3 results for obesity drug retatrutide

retatrutide Eli Lilly phase‑3 trial obesity FDA filing

Eli Lilly announced that its experimental obesity drug retatrutide produced significant weight loss in two phase‑3 trials. In participants with obesity and cardiovascular disease, the highest dose led to an average loss of up to 22.6 % of body weight after 80 weeks. In a separate trial of people with type‑2 diabetes, participants lost up to 20.8 % of their weight over the same period. The drug also lowered HbA1c by 1.6 percentage points in the diabetic group. The most frequent side effects were digestive issues such as nausea and diarrhoea, and a small subgroup showed a higher incidence of serious cardiovascular events. Retatrutide acts on three hormonal pathways – GLP‑1, GIP and glucagon receptors – to curb appetite and improve metabolic control. Eli Lilly plans to file a Biologics License Application with the U.S. Food and Drug Administration in the first quarter of 2027. The company previously reported strong sales growth for its GLP‑1 drugs tirzepatide (Mounjaro/Zepbound), which rose 125 % and 80 % respectively in Q1 2026, underscoring the importance of its pipeline of weight‑loss treatments.

Entities

Arthur J. Gallagher & Co. · Eli Lilly and Company · Gilead Sciences Inc. · Glenmede Trust Co. NA · Globe Life Inc. · Healthcare of Ontario Pension Plan Trust Fund · MassMutual Private Wealth & Trust FSB · Morgan Stanley · Mounjaro · Pacer Advisors Inc. · Retatrutide · State Treasurer of North Carolina

Claims

What the coverage asserts, and how many sources carry each claim.

  • [● 2 SOURCES] Eli Lilly plans to submit a Biologics License Application for retatrutide to the FDA in the first quarter of 2027. www.fool.com · www.techno-science.net
  • [○ 1 SOURCE] The most common adverse events of retatrutide were digestive issues such as nausea and diarrhoea. www.techno-science.net
  • [○ 1 SOURCE] Retatrutide targets GLP‑1, GIP and glucagon receptors. www.techno-science.net
  • [○ 1 SOURCE] Retatrutide caused up to 22.6 % average weight loss in obese participants after 80 weeks in a phase‑3 trial. www.techno-science.net
  • [○ 1 SOURCE] Eli Lilly’s GLP‑1 drug tirzepatide (Mounjaro/Zepbound) saw sales increase 125 % and 80 % respectively in Q1 2026. www.fool.com
  • [○ 1 SOURCE] In diabetic participants, retatrutide reduced HbA1c by 1.6 percentage points at the highest dose. www.techno-science.net
  • [○ 1 SOURCE] Retatrutide caused up to 20.8 % weight loss in participants with type‑2 diabetes after 80 weeks in a phase‑3 trial. www.techno-science.net
  • [○ 1 SOURCE] A small subgroup in the trial experienced a higher rate of serious cardiovascular events. www.techno-science.net

Sources

Eli Lilly Is Up 7% in 2026 and Has Major Catalysts on the Way. Is the Rally Just Getting Started? | The Motley Fool [www.fool.com]
Glenmede Trust Co. NA Acquires 16,044 Shares of Arthur J. Gallagher & Co. $AJG [www.marketbeat.com]
Retatrutide: resultados positivos y retraso en la aprobación por Eli Lilly [www.nutridieta.com]
Qualys (NASDAQ:QLYS) Updates FY 2026 Earnings Guidance [www.marketbeat.com]
💊 Un médicament expérimental confirme son potentiel contre l’obésité - Actualités - Techno-Science [www.techno-science.net]